ResMed
RMD | NYSE
$238.19
-$1.34 (-0.56%)
At close: Nov 16, 2026, 4:00 PM ET
$238.94
+$0.75 (+0.31%)
After-hours:
Nov 16, 2026, 7:37 PM ET
ResMed Company Profile
Company profile explainedCompany Profile
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Keith Serzen | Senior Advisor to the CEO |
| Michael J. Farrell | Chief Executive Officer & Chairman |
| Aaron Bloomer | Chief Financial Officer |
| Alastair Robertson | Chief Information Officer |
| Michael Rider | Chief Legal Officer & Secretary |
| Vered Keisar | Chief People Officer |
| Yvonne-Katrin Pucknat | Chief Marketing Officer |
| Brett A. Sandercock | Advisor |
| Carlos Nunez | Chief Medical Officer |
| Jim Ellis | Chief Compliance Officer |
| Justin Leong | Chief Product Officer |
| Michael Fliss | Chief Revenue Officer |
| Peter C. Farrell | Founder, Chair Emeritus & Non-Executive Director |
| Sallilyn Schwartz | Chief Communications and Investor Relations Officer |
| Shane Azzi | Chief Supply Chain Officer |
| Todd Friedman | Chief Information Security Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 26, 2026 | 4 | Filing |
| Oct 08, 2026 | 4 | Filing |
| Oct 01, 2026 | ARS | Filing |
| Oct 01, 2026 | DEFA14A | Filing |
| Oct 01, 2026 | DEF 14A | Filing |
| Oct 01, 2026 | 4/A | [Amend] Filing |
| Oct 01, 2026 | 4 | Filing |
| Oct 01, 2026 | 4 | Filing |
ResMed
| Country | United States |
| IPO Date | Jun 2, 1995 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 11,370 |
| CEO | Michael J. Farrell |
Contact Details
9001 Spectrum Center Boulevard San Diego,
California 92123 United States
Stock Details
| Ticker Symbol | RMD |
| Exchange | NYSE |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000943819 |
| CUSIP Number | 761152107 |
| ISIN Number | US7611521078 |
| SIC Code | 3841 |
Recent News
- 15 days ago / fool.comResMed: 3 Key Takeaways for Long-Term Investors
- 18 days ago / zacks.comResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
- 18 days ago / zacks.comRMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
- 18 days ago / marketbeat.comWhat ResMed (RMD) Said on Its Q1 Earnings Call
- 18 days ago / seekingalpha.comResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
- 18 days ago / zacks.comResMed (RMD) Beats Q1 Earnings and Revenue Estimates
- 18 days ago / benzinga.comResMed Q1 2027 Earnings Call Transcript
- 18 days ago / globenewswire.comResmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
- 20 days ago / zacks.comUnlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
- 25 days ago / zacks.comWill ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
Add to Watchlist
Select watchlists to add or remove RMD